kw.\*:("Aptiganel")
Results 1 to 7 of 7
Selection :
Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteersMUIR, K. W; GROSSET, D. G; LEES, K. R et al.Clinical neuropharmacology. 1997, Vol 20, Num 4, pp 311-321, issn 0362-5664Article
Protective effects of aptiganel HCl (Cerestat®) following controlled cortical impact injury in the ratKROPPENSTEDT, S.-N; SCHNEIDER, G.-H; THOMALE, U.-W et al.Journal of neurotrauma. 1998, Vol 15, Num 3, pp 191-197, issn 0897-7151Article
Differential immediate-early gene expression in ovine brain after Cardiopulmonary bypass and hypothermic circulatory arrestBOKESCH, P. M; SEIRAFI, P. A; WARNER, K. G et al.Anesthesiology (Philadelphia). 1998, Vol 89, Num 4, pp 961-968, issn 0003-3022Article
Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic strokeDYKER, A. G; EDWARDS, K. R; FAYAD, P. B et al.Stroke (1970). 1999, Vol 30, Num 10, pp 2038-2042, issn 0039-2499Article
Aptiganel hydrochloride in acute ischemic Stroke: A randomized controlled trialALBERS, Gregory W; GOLDSTEIN, Larry B; HALL, David et al.JAMA, the journal of the American Medical Association. 2001, Vol 286, Num 21, pp 2673-2682, issn 0098-7484Article
Glutamate AMPA receptor antagonist treatment for ischaemic strokeAKINS, Paul T; ATKINSON, Richard P.Current medical research and opinion. Supplement. 2002, Vol 18, Num 2, pp s9-s13, issn 0141-9951Article
Cerestat and other NMDA antagonists in ischemic strokeLEES, K. R.Neurology. 1997, Vol 49, Num 5, pp S66-S69, issn 0028-3878, SUP4Conference Paper